Who are Dasabuvir mini tablet's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Viekira Pak ± ribavirin, Grazaoprevir/Elbasavir, Elbasvir / Grazoprevir Oral Tablet [Zepatier], Sofosbuvir and Daclatasvir for 24 weeks, EBR/GZR (elbasvir/grazoprevir), ABT450r-ABT267-ABT333 +/- Ribavirin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dasabuvir-mini-tablet.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Dasabuvir mini tablet — Competitive Intelligence Brief

Dasabuvir mini tablet (Dasabuvir mini tablet) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NS5A inhibitor. Area: Infectious Disease.

phase 2 NS5A inhibitor NS5A Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Dasabuvir mini tablet (Dasabuvir mini tablet) — AbbVie. NS5A replication complex inhibitor

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Dasabuvir mini tablet TARGET	Dasabuvir mini tablet	AbbVie	phase 2	NS5A inhibitor	NS5A
Viekira Pak ± ribavirin	Viekira Pak ± ribavirin	Massachusetts General Hospital	marketed	Direct-acting antiviral (DAA) combination	HCV NS5A protein, HCV NS3/4A serine protease
Grazaoprevir/Elbasavir	Grazaoprevir/Elbasavir	The HIV Netherlands Australia Thailand Research Collaboration	marketed	Direct-acting antiviral (DAA) combination	HCV NS3/4A protease and NS5A protein
Elbasvir / Grazoprevir Oral Tablet [Zepatier]	Elbasvir / Grazoprevir Oral Tablet [Zepatier]	University of Maryland, Baltimore	marketed	Direct-acting antiviral (DAA) combination	HCV NS5A protein and HCV NS3/4A serine protease
Sofosbuvir and Daclatasvir for 24 weeks	Sofosbuvir and Daclatasvir for 24 weeks	ANRS, Emerging Infectious Diseases	marketed	Direct-acting antiviral (DAA) combination	HCV NS5B RNA polymerase and HCV NS5A protein
EBR/GZR (elbasvir/grazoprevir)	EBR/GZR (elbasvir/grazoprevir)	University of Florida	marketed	Direct-acting antiviral (DAA) combination; NS5A inhibitor + NS3/4A protease inhibitor	Hepatitis C virus NS5A protein and NS3/4A serine protease
ABT450r-ABT267-ABT333 +/- Ribavirin	ABT450r-ABT267-ABT333 +/- Ribavirin	Ottawa Hospital Research Institute	marketed	Direct-acting antiviral (DAA) combination	HCV NS3/4A protease, NS5A protein, NS5B polymerase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NS5A inhibitor class)

Bristol-Myers Squibb · 2 drugs in this class
AbbVie · 1 drug in this class
Ferrer Internacional S.A. · 1 drug in this class
Merck Sharp & Dohme LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Dasabuvir mini tablet — Competitive Intelligence Brief. https://druglandscape.com/ci/dasabuvir-mini-tablet. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab